Skip to main content
IMAGION BIOSYSTEMS LIMITED logo

IMAGION BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · IBX ISIN · AU000000IBX6 ASX Professional, scientific and technical activities
Open in API
Filings indexed 658 across all filing types
Latest filing 2026-05-25 Declaration of Voting R…
Country AU Australia
Listing ASX IBX

About IMAGION BIOSYSTEMS LIMITED

https://imagionbiosystems.com/

Imagion Biosystems Limited is a medical technology company specializing in the development of advanced diagnostic imaging solutions. The company's proprietary MagSense technology utilizes superparamagnetic iron oxide nanoparticles to detect specific cancer cells non-invasively. By functionalizing these nanoparticles with targeting antibodies, the system can identify the presence and location of malignancies, such as HER2-positive breast cancer, using highly sensitive magnetic sensors. This approach aims to provide a safer, more accurate alternative to traditional biopsy and imaging methods by eliminating the need for ionizing radiation or radioactive tracers. The technology is designed to improve clinical decision-making through earlier detection and better staging of diseases, ultimately enhancing patient outcomes in oncology.

Recent filings

Filing Released Lang Actions
Results of Annual General Meeting 2 pages 286.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement titled “Results of Annual General Meeting” and provides detailed vote counts, proxy instructions, and outcomes for ten AGM resolutions in accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act. It reports official shareholder voting results rather than containing AGM presentation materials or a full report. This matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-25 English
Investor Presentation 21 pages 5.2MB
Investor Presentation Classification · 92% confidence The document is a slide-based company overview and investor deck containing forward-looking statements, technology description, clinical trials, pipeline, and market information intended for investors. It is not a formal regulatory filing, earnings release, or management certificate. It matches the definition of an Investor Presentation (Code: IP).
2026-05-25 English
IBX Chairman's AGM Address 3 pages 357.3KB
AGM Information Classification · 92% confidence The document is the text of the Executive Chairman’s Address delivered at the company’s Annual General Meeting, provided under ASX Listing Rule 3.13.3. It clearly constitutes AGM materials rather than a standalone financial report, earnings release, or investor presentation. Therefore it falls under AGM Information.
2026-05-25 English
Change of Director's Interest Notice - Robert Proulx 4 pages 418.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities holdings of a company director, including the number and class of securities held before and after the change, the nature of the change (expiry of unlisted performance options), and other related information. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing'. The length and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure of insider trading activity.
2026-05-07 English
Notification of cessation of securities - IBX 5 pages 16.4KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for Imagion Biosystems Limited. It includes specific information about the securities that have ceased, reasons for cessation, and updated issued capital figures. This type of document is a regulatory announcement notifying the market and shareholders about changes in the company's issued securities, specifically the cessation of certain options due to expiry without exercise. It is not a financial report, earnings release, or management discussion. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like share issue or capital change (SHA) or director dealings (DIRS). The document length is 4515 characters, which is relatively short and focused on the cessation notification, consistent with RNS filings.
2026-05-03 English
Notice of Annual General Meeting/Proxy Form 32 pages 953.7KB
Proxy Solicitation & Information Statement Classification · 87% confidence The document is the formal Notice of Annual General Meeting (AGM) together with the Explanatory Statement and Proxy Form, sent to shareholders to provide information on proposed resolutions and to solicit their votes prior to the virtual meeting. It does not present actual AGM presentations or slides, nor is it the full annual report or earnings release. It corresponds to the category for materials sent to shareholders to request votes and provide meeting information (Proxy Solicitation & Information Statement).
2026-04-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.